Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial

Prostate Cancer and Prostatic Diseases volume 10, pages 155–159 (2007)Cite this article

An Erratum to this article was published on 13 May 2008

Abstract

This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Qmax) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged ⩾50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Qmax increased significantly from baseline at day 8 with alfuzosin (P<0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P=0.07 versus placebo) and day 29 (P=0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Qmax and LUTS maintained through 1 month of treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. AUA Practice Guidelines Committee. AUA guideline on management of benign prostatic hyperplasia (2003). Chapter 1: diagnosis and treatment recommendations. J Urol 2003; 170: 530–547.

  2. Chapple CR, Aubry ML, James S, Greengrass PM, Burnstock G, Turner-Warwick RT et al. Characterisation of human prostatic adrenoceptors using pharmacology receptor binding and localisation. Br J Urol 1989; 63: 487–496.

    Article  CAS  Google Scholar 

  3. Djavan B, Marberger M . A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 1999; 36: 1–13.

    Article  CAS  Google Scholar 

  4. Buzelin JM, Roth S, Geffriaud-Ricouard C, Delauche-Cavallier MC . Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. Eur Urol 1997; 31: 190–198.

    Article  CAS  Google Scholar 

  5. The Italian Alfuzosin Co-Operative Group. Safety, efficacy and impact on patients' quality of life of a long-term treatment with the alpha(1)-blocker alfuzosin in symptomatic patients with BPH. Eur Urol 2000; 37: 680–686.

  6. Lukacs B, Grange JC, Comet D . One-year follow-up of 2829 patients with moderate to severe lower urinary tract symptoms treated with alfuzosin in general practice according to IPSS and a health-related quality-of-life questionnaire. BPM Group in General Practice. Urology 2000; 55: 540–546.

    Article  CAS  Google Scholar 

  7. Sanchez-Chapado M, Guil M, Alfaro V, Badiella L, Fernandez-Hernando N . Safety and efficacy of sustained-release alfuzosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia in 3095 Spanish patients evaluated during general practice. Eur Urol 2000; 37: 421–427.

    Article  CAS  Google Scholar 

  8. Roehrborn CG, Van Kerrebroeck P, Nordling J . Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. BJU Int 2003; 92: 257–261.

    Article  CAS  Google Scholar 

  9. Marks LS, Roehrborn CG, Gittelman M, Kim D, Forrest J, Jacobs S . First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. Urology 2003; 62: 888–893.

    Article  Google Scholar 

  10. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewite RC, Holtgrewe HL, Mebust WK et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549–1557; discussion 1564.

    Article  CAS  Google Scholar 

  11. Barry M, Batista J, Donovan J et al. Measuring the symptoms and health impact of benign prostatic hyperplasia and its treatments. In: Chatelain C, Denis L, Foo K, Khoury S, McConnell J (eds). Benign Prostatic Hyperplasia. Health Publication: United Kingdom, 2001, pp 203–220.

    Google Scholar 

  12. Barry MJ, Fowler Jr FJ, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK . Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of the American Urological Association. Med Care 1995; 33: AS145–AS155.

    Article  CAS  Google Scholar 

  13. Van Kerrebroeck P, Jardin A, Laval KU, van Cangh P . Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. Eur Urol 2000; 37: 306–313.

    Article  CAS  Google Scholar 

  14. Roehrborn CG . Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. Urology 2001; 58: 953–959.

    Article  CAS  Google Scholar 

  15. Nordling J . Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. BJU Int 2005; 95: 1006–1012.

    Article  CAS  Google Scholar 

  16. McKeage K, Plosker GL . Alfuzosin: a review of the therapeutic use of the prolonged-release formulation given once daily in the management of benign prostatic hyperplasia. Drugs 2002; 62: 633–653.

    Article  CAS  Google Scholar 

  17. Roehrborn CG . Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. BJU Int 2006; 97: 734–741.

    Article  CAS  Google Scholar 

  18. Van Kerrebroeck P, Jardin A, van Cangh P, Laval KU . Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension study. Eur Urol 2002; 41: 54–60; discussion 60-61.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This study was sponsored by Sanofi-Aventis.

Author information

Authors and Affiliations

  1. Department of Urology, Case Medical Center, Cleveland, OH, USA

    M I Resnick

  2. Department of Urology, Middlesex Hospital, London, UK

    C G Roehrborn

Authors
  1. M I Resnick
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C G Roehrborn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M I Resnick.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Resnick, M., Roehrborn, C. Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. Prostate Cancer Prostatic Dis 10, 155–159 (2007). https://doi.org/10.1038/sj.pcan.4500925

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.pcan.4500925

Keywords

This article is cited by

Search

Advanced search

Quick links